|
1
|
Le Chevalier T: Adjuvant chemotherapy for
resectable non-small-cell lung cancer: where is it going? Ann
Oncol. 21(Suppl 7): vii196–vii198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Azzoli CG, Park BJ, Pao W, Zakowski M and
Kris MG: Molecularly tailored adjuvant chemotherapy for resected
non-small cell lung cancer: a time for excitement and equipoise. J
Thorac Oncol. 3:84–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dziadziuszko R and Hirsch FR: Advances in
genomic and proteomic studies of non-small-cell lung cancer:
clinical and translational research perspective. Clin Lung Cancer.
9:78–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taillade L, Penault-Llorca F, Boulet T, et
al: Immunohistochemichal expression of biomarkers: a comparative
study between diagnostic bronchial biopsies and surgical specimens
of non-small cell lung cancer. Ann Oncol. 18:1043–1050. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toschi L and Cappuzzo F: Impact of
biomarkers on non-small cell lung cancer treatment. Target Oncol.
5:5–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bowden NA: Nucleotide excision repair: why
is it not used to predict response to platinum-based chemotherapy?
Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simon GR, Ismail-Khan R and Bepler G:
Nuclear excision repair-based personalized therapy for non-small
cell lung cancer: from hypothesis to reality. Int J Biochem Cell
Biol. 39:1318–1328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosell R, Lord RV, Taron M and Reguart N:
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Friboulet L, Barrios-Gonzales D, Commo F,
et al: Molecular characteristics of ERCC1-negative versus
ERCC1-positive tumors in resected NSCLC. Clin Cancer Res.
17:5562–5572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bepler G: Pharmacogenomics: a reality or
still a promise? Lung Cancer. 54(Suppl 2): S3–S7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Custodio A, Mendez M and Provencio M:
Targeted therapies for advanced non-small-cell lung cancer: current
status and future implications. Cancer Treat Rev. 38:36–53. 2012.
View Article : Google Scholar
|
|
12
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gossage L and Madhusudan S: Current status
of excision repair cross complementing-group 1 (ERCC1) in cancer.
Cancer Treat Rev. 33:565–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Vergnenegre A, Liu B, et al:
Biomarkers in lung oncology. Pulm Pharmacol Ther. 23:508–514. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen J, Emara N, Solomides C, Parekh H and
Simpkins H: Resistance to platinum-based chemotherapy in lung
cancer cell lines. Cancer Chemother Pharmacol. 66:1103–1111. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosell R, Cobo M, Isla D, Camps C and
Massuti B: Pharmacogenomics and gemcitabine. Ann Oncol. 17(Suppl
5): v13–v16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O’Brien CP, Taylor SE, O’Leary JJ and Finn
SP: Molecular testing in oncology: problems, pitfalls and progress.
Lung Cancer. 83:309–315. 2014. View Article : Google Scholar
|
|
18
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takenaka T, Yoshino I, Kouso H, et al:
Combined evaluation of Rad51 and ERCC1 expressions for sensitivity
to platinum agents in non-small cell lung cancer. Int J Cancer.
121:895–900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tiseo M, Bordi P, Bortesi B, et al: A
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and
predictive factors in advanced NSCLC treated with or without
cisplatin. Br J Cancer. 108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosell R, Cecere F, Santarpia M, Reguart N
and Taron M: Predicting the outcome of chemotherapy for lung
cancer. Curr Opin Pharmacol. 6:323–331. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ota S, Ishii G, Goto K, et al:
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen
predicts survival in advanced non-small-cell lung cancer treated
with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009.
View Article : Google Scholar
|
|
23
|
Wachters FM, Wong LS, Timens W, Kampinga
HH and Groen HJ: ERCC1, hRad51 and BRCA1 protein expression in
relation to tumour response and survival of stage III/IV NSCLC
patients treated with chemotherapy. Lung Cancer. 50:211–219. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Filipits M and Pirker R: Predictive
markers in the adjuvant therapy of non-small cell lung cancer. Lung
Cancer. 74:355–363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Filipits M, Haddad V, Schmid K, et al:
Multidrug resistance proteins do not predict benefit of adjuvant
chemotherapy in patients with completely resected non-small cell
lung cancer: International Adjuvant Lung Cancer Trial Biologic
Program. Clin Cancer Res. 13:3892–3898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Voortman J, Goto A, Mendiboure J, et al:
MicroRNA expression and clinical outcomes in patients treated with
adjuvant chemotherapy after complete resection of non-small cell
lung carcinoma. Cancer Res. 70:8288–8298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Filipits M, Pirker R, Dunant A, et al:
Cell cycle regulators and outcome of adjuvant cisplatin-based
chemotherapy in completely resected non-small-cell lung cancer: the
International Adjuvant Lung Cancer Trial Biologic Program. J Clin
Oncol. 25:2735–2740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan H, Li L, Zuo CT, Mao NQ, Chen FL,
Zhang W and Tang BJ: Relationship between combined multigene
detection and response to adjuvant chemotherapy in early-stage
non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 30:528–531.
2008.PubMed/NCBI
|
|
29
|
Elbashir SM, Lendeckel W and Tuschl T: RNA
interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev.
15:188–200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang J, Liang X, Zhou X, Huang R, Chu Z
and Zhan Q: ERCC1 expression as a prognostic and predictive factor
in patients with non-small cell lung cancer: a meta-analysis. Mol
Biol Rep. 39:6933–6942. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tepeli E, Caner V, Buyukpinarbasili N,
Cetin GO, Duzcan F, Elmas L and Bagci G: Expression of ERCC1 and
its clinicopathological correlations in non-small cell lung cancer.
Mol Biol Rep. 39:335–341. 2012. View Article : Google Scholar
|
|
32
|
Koc E, Caner V, Buyukpinarbasili N, Tepeli
E, Turk NS, Ozan Cetin G and Bagci G: The determination of
relationship between ‘excision repair cross-complementing group 1’
(ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and
clinicopathological parameters in non-small cell lung cancer. Mol
Biol Rep. 39:375–380. 2012. View Article : Google Scholar
|
|
33
|
Yang Y and Xian L: The association between
the ERCC1/2 polymorphisms and the clinical outcomes of the
platinum-based chemotherapy in non-small cell lung cancer (NSCLC):
a systematic review and meta-analysis. Tumour Biol. 35:2905–2921.
2014. View Article : Google Scholar
|
|
34
|
Friboulet L, Olaussen KA, Pignon JP, et
al: ERCC1 isoform expression and DNA repair in non-small-cell lung
cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar :
|
|
36
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
37
|
Chang IY, Kim MH, Kim HB, Lee DY, Kim SH,
Kim HY and You HJ: Small interfering RNA-induced suppression of
ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Biochem Biophys Res Commun. 327:225–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
